Disruptive Technology

Our solution employs forefront synthetic biology techniques to genetically engineer anaerobic, spore-forming bacteria with CRISPR-Cas9 gene editing and allelic exchange technology. These plasmid and antibiotic-free spores become delivery vehicles that secrete therpautics only at the core of hypoxic/necrotic tumours.

In practice this means that we can administer the engineered chassis including the therapeutic compound to the patient.